Friday, August 02, 2019 7:26:41 PM
https://www.angelmd.co/en/startups/qrons-inc
Product Overview
We have two products candidates for treating TBIs, both integrating proprietary, modified mesenchymal stem cells (“MSCs”) and smart synthetic material. QS100TM is an injury specific, 3D printable, implantable MSCs-synthetic hydrogel, to treat penetrating brain injuries and QS200TM is an injectable MSCs-synthetic
PRODUCT SNAPSHOT
Product Status: Prototype Complete
Clinical Trials: Pre-Clinical
Patents: Provisional
Market Size: $5B
COMPETITIVE ADVANTAGE
We believe we are the only Company working on a treatment for TBI. Other companies are working on detection systems, but not treating the TBI.
$QRON
Recent QRON News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/12/2023 01:36:38 AM
- Qrons Announces the Signing of a License Agreement Term Sheet as Part of New Research Program to Experiment and Commercialize the Therapeutic Effect of Certain Tellurium Based Compounds on Antibiotic Resistance Bacterial Infections, Sepsis and TBIs • InvestorsHub NewsWire • 07/25/2023 03:14:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 07:24:55 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM